Anti-inflammatory Effects of Rebamipide According to Helicobacter pylori Status in Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in China—STARS Study

Du, Yiqi; Li, Zhao‐Shen; Zhan, Xi; Chen, Jie; Gao, Jun; Yang, Gong; Ren, Jianlin; He, Liqing; Zhang, Zhijian; Guo, Xiaozhong; Jian-shen, WU; Tian, Ziqiang; Shi, Ruihua; Jiang, Bo; Fang, Dian‐Chun; Li, Youming

doi:10.1007/s10620-007-0180-z

Cited by 28 publications

(26 citation statements)

References 31 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, we detected decreased levels of Rothia, Granulicatella, Streptococcus, Fusobacterium, Gemella, Haemophilus, Neisseria, and Porphyromonas in CEG patients with YTC. All of these 8 genera have been described in normal populations of healthy oral microbiota45678910111213141516171819202122232425262728293031. An increasing trend in these bacteria was observed after therapy, albeit not statistically significant (Fig.…”

Section: Discussionmentioning

confidence: 78%

“…Chronic erosive gastritis (CEG) is a very common gastrointestinal disease in China12. Patients with CEG always present with various gastrointestinal tract symptoms and histological changes in gastric mucosa leading to decreased quality of life13. Currently, TCM practitioners often use Chinese herbal medicines to successfully treat gastrointestinal disorders categorized as damp-heat syndrome (i.e., CEG, enteritis, gastric ulcer, and gastralgia), which is mainly characterized by YTC14.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Bacillus as a potential diagnostic marker for yellow tongue coating

Cai

Yang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Observation of tongue coating, a foundation for clinical diagnosis and treatment in traditional Chinese medicine (TCM), is a major indicator of the occurrence, development, and prognosis of disease. The biological basis of tongue diagnosis and relationship between the types and microorganisms of tongue coating remain elusive. Thirteen chronic erosive gastritis (CEG) patients with typical yellow tongue coating (YTC) and ten healthy volunteers with thin white tongue coating (WTC) were included in this study. Patients were provided a 2-course targeted treatment of a herbal medicine Ban Xia Xie Xin decoction, traditionally prescribed for CEG patients with YTC, to evaluate the relationship between tongue coating microbiota and diagnosis of CEG with typical YTC. The tongue coating segregation structure was determined using Illumina Miseq sequencing of the V4–V5 region of the 16S ribosomal RNA gene. Bacillus was significantly observed only in CEG patients with YTC, but not in patients who received the decoction. YTC (n = 22) and WTC (n = 29) samples were collected for bacterial culturing to illustrate the relationship between Bacillus and YTC. The Bacillus positivity rate of YTC samples was 72.7%; Bacillus was not observed in WTC samples. In conclusion, Bacillus was strongly associated with YTC.

show abstract

Section: Discussionmentioning

confidence: 78%

mentioning

confidence: 99%

Bacillus as a potential diagnostic marker for yellow tongue coating

Cai

Yang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In a recent multicenter randomized clinical trial (RCT), rebamipide (Mucosta; Otsuka Pharmaceutical, Tokyo, Japan) was reported to be efficacious for the treatment of large gastric ulcers after Helicobacter pylori eradication [9]. In randomized controlled studies, rebamipide prevented nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcers, accelerated gastric ulcer healing, and suppressed mucosal inflammation in chronic erosive gastritis [10][11][12]. The action of rebamipide is explained at least in part by the increased expression of epidermal growth factor (EGF) and EGF receptors on epithelial cells [13,14].…”

Section: Introductionmentioning

confidence: 99%

Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection—a randomized controlled study

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Another recent placebo-controlled trial also found that rebamipide is as effective as omeprazole in treating H. pylori-positive gastric ulcers after eradication (5). In randomized controlled studies, rebamipide has been found to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcers, accelerate gastric ulcer healing and suppress mucosal inflammation in patients with chronic erosive gastritis (6,7). Recently, several studies (8)(9)(10)(11)(12)(13)(14) have examined the efficacy of rebamipide and PPI combination therapy for the treatment of ESD-induced ulcers.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Proton Pump Inhibitors (PPIs) Plus Rebamipide for Endoscopic Submucosal Dissection-induced Ulcers: A Meta-analysis

Wang

Guo

et al. 2014

Intern. Med.

View full text Add to dashboard Cite

Objective To compare the efficacy of proton pump inhibitors (PPIs) with rebamipide versus PPIs alone for the treatment of ulcers after endoscopic submucosal dissection (ESD). Methods PubMed, Web of Science, Medline, Embase, the Cochrane Central Register of Controlled Trials and China Naitonal Knowledge Infrastructure were searched up to the end of October 2013 in order to identify all randomized controlled trials reporting the effects of PPIs plus rebamipide on healing ulcers after ESD. The outcome measurement was complete ulcer healing. Results A total of six studies involving 724 patients were included. The pooled data suggested a significantly higher rate of ulcer healing after endoscopic therapy among patients treated with PPIs plus rebamipide than among those treated with PPIs alone [odds ratio (OR)=2.40, 95% confidence interval (CI): 1.68-3.44]. The subgroup analysis showed PPI plus rebamipide therapy to be more effective in healing ESD-induced ulcers than treatment with PPIs alone after both four (OR=2.22, 95%CI: 1.53-3.24) and eight weeks of treatment (OR=3.19, 95%CI: 1.22-8.31). In addition, the combination therapy was found to be significantly more effective than the use of PPIs alone for all ESD ulcers greater than 20 mm in size (OR=4.77, 95%CI: 2.22-10.26). There were no significant differences between the treatment groups with regard to ulcer location (low, middle or upper stomach) or the presence of absence of H. pylori infection. No serious adverse events were observed in either group. Conclusion The results of this meta-analysis suggest that treatment with PPIs plus rebamipide is superior to PPI monotherapy for healing ESD-induced ulcers over four weeks, particularly large ulcers. However, more well-designed trials are needed to confirm these findings.

show abstract

Anti-inflammatory Effects of Rebamipide According to Helicobacter pylori Status in Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in China—STARS Study

Cited by 28 publications

References 31 publications

Bacillus as a potential diagnostic marker for yellow tongue coating

Bacillus as a potential diagnostic marker for yellow tongue coating

Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection—a randomized controlled study

Efficacy and Safety of Proton Pump Inhibitors (PPIs) Plus Rebamipide for Endoscopic Submucosal Dissection-induced Ulcers: A Meta-analysis

Contact Info

Product

Resources

About